StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)

Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%

Amgen operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Amgen's operating cash flow for the twelve months ending Sep 30, 2026 was $12.04B, down 8.3% year over year. For fiscal 2025 it was $9.96B, down 13.3% from the year before. Over ten years it grew 0.2% a year on average. The highest annual figure on record is $11.49B in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.96B-13.3%
FY2024Dec 31, 2024$11.49B+35.6%
FY2023Dec 31, 2023$8.47B-12.9%
FY2022Dec 31, 2022$9.72B+5.0%
FY2021Dec 31, 2021$9.26B-11.8%
FY2020Dec 31, 2020$10.50B+14.7%
FY2019Dec 31, 2019$9.15B-19.0%
FY2018Dec 31, 2018$11.30B+1.1%
FY2017Dec 31, 2017$11.18B+7.9%
FY2016Dec 31, 2016$10.35B+6.4%
FY2015Dec 31, 2015$9.73B+8.7%
FY2014Dec 31, 2014$8.95B+42.3%
FY2013Dec 31, 2013$6.29B+7.0%
FY2012Dec 31, 2012$5.88B+14.9%
FY2011Dec 31, 2011$5.12B-11.5%
FY2010Dec 31, 2010$5.79B-8.7%
FY2009Dec 31, 2009$6.34B+5.8%
FY2008Dec 31, 2008$5.99B+10.9%
FY2007Dec 31, 2007$5.40B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$4.24B-9.5%
Q2 FY2026Jun 30, 2026$4.00B+75.5%
Q1 FY2026Mar 31, 2026$2.19B+57.4%
Q4 FY2025Dec 31, 2025$1.60B-66.4%
Q3 FY2025Sep 30, 2025$4.68B+31.2%
Q2 FY2025Jun 30, 2025$2.28B-7.3%
Q1 FY2025Mar 31, 2025$1.39B+101.9%
Q4 FY2024Dec 31, 2024$4.77B+786.8%
Q3 FY2024Sep 30, 2024$3.57B+29.4%
Q2 FY2024Jun 30, 2024$2.46B-40.2%
Q1 FY2024Mar 31, 2024$689.00M-35.2%
Q4 FY2023Dec 31, 2023$538.00M-79.7%
Q3 FY2023Sep 30, 2023$2.76B-7.3%
Q2 FY2023Jun 30, 2023$4.11B+112.9%
Q1 FY2023Mar 31, 2023$1.06B-50.8%
Q4 FY2022Dec 31, 2022$2.65B-5.7%
Q3 FY2022Sep 30, 2022$2.98B+41.5%
Q2 FY2022Jun 30, 2022$1.93B-10.4%
Q1 FY2022Mar 31, 2022$2.16B-35.7%
Q4 FY2021Dec 31, 2021$2.81B-1.2%
Q1 FY2021Mar 31, 2021$2.10B-1.4%
Q4 FY2020Dec 31, 2020$2.15B+52.3%
Q3 FY2020Sep 30, 2020$3.37B+82.5%
Q2 FY2020Jun 30, 2020$2.84B-11.0%
Q1 FY2020Mar 31, 2020$2.13B-34.8%
Q2 FY2019Jun 30, 2019$1.41B-32.7%
Q1 FY2019Mar 31, 2019$1.85B-32.3%
Q4 FY2018Dec 31, 2018$3.19B+6.0%
Q3 FY2018Sep 30, 2018$3.27B-5.2%
Q2 FY2018Jun 30, 2018$2.10B-9.6%
Q1 FY2018Mar 31, 2018$2.73B+14.3%
Q4 FY2017Dec 31, 2017$3.01B-2.8%
Q3 FY2017Sep 30, 2017$3.45B+29.8%
Q2 FY2017Jun 30, 2017$2.33B-13.1%
Q1 FY2017Mar 31, 2017$2.39B–
Q4 FY2016Dec 31, 2016$3.10B–
Q3 FY2016Sep 30, 2016$2.66B–
Q2 FY2016Jun 30, 2016$2.68B–

More Amgen figures

See a number that looks wrong?